To exploit a novel strategy to regulate T-cell-mediated immunity, we established human and murine modified dendritic cells (DCs) with potent immunoregulatory property (designed as regulatory DCs), which displayed moderately high expression levels of major histocompatibility complex (MHC) molecules and extremely low levels of costimulatory molecules compared to their normal counterparts. Unlike human normal Thus, the modulation of T cell-mediated immunity by regulatory DCs provides a novel therapeutic approach for immunopathogenic diseases.
Introduction
Dendritic cells (DCs) are unique professional major antigen (Ag)-presenting cells (APCs) capable of stimulating naive T cells in the primary immune response, and are more potent APCs than monocytes/macrophages or B cells. 1 The treatment of normal immature DCs (iDCs) with interleukin (IL)-10 caused a downregulation in the expressions of major histocompatibility complex (MHC) and costimulatory molecules, leading to a suppression of their T cell-stimulatory ability 2 as well as an induction of anergic T cells. 3, 4 Recently, repetitive stimulation of human naive CD4 + T cells with allogeneic normal iDC not only induce T-cell anergy but also generated CD4 + CD25 + CD152 + regulatory T (Tr) cells from their naive subsets. 5 Furthermore, a single injection of antigenic peptide-pulsed normal iDCs led to an appearance of Ag-specific IL-10-producing CD8 + T cells in healthy individuals. 6 However, the clinical application of self Ag-pulsed or allogeneic/xenogeneic normal iDCs may not be suitable for the treatment of autoimmune diseases or for allogeneic/ xenogeneic organ transplantation, because the injected normal iDCs are not likely to remain immature in vivo after recirculation and home into the damaged tissue where chronic inflammation is always present. 7 Therefore, further development of DCs with potent negative regulatory ability for T cells is thought to facilitate their use for the prevention and the treatment of immunopathogenic diseases.
To exploit a novel strategy involving the use of DCs for the regulation of T-cell-mediated immunity, we examined the effect of human and murine modified DCs with potent immunoregulatory property (designed as regulatory DCs) on allogeneic/ xenogeneic T-cell responses in vivo and in vitro. ) in the presence or absence of human IL-2 (100 U/ml) for 3 days. After incubation, human T cells were negatively selected with anti-I-K d mAb (BD PharMingen) plus goat anti-mouse IgG mAb-conjugated immunomagnetic beads. These T-cell preparations contained <0.1% I-K d+ cells as assessed by FACS analysis. Cells were rested in medium containing human IL-2 (10 U/ml) for 3 days before use.
Mixed leukocyte reaction (MLR)
Human T-cell subsets (10 5 ) were cultured in 96-well plates (Coster, Cambridge, MA) with various numbers of irradiated (15 Gy) allogeneic/xenogeneic DCs in the presence or absence of human IL-2 (100 U/ml). Thymidine incorporationwas measured as counts per minute (cpm) for the indicated days after an 18-h pulse with [ 3 H]thymidine.
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Cytotoxic T lymphocytes (CTL) assay
Ag-specific CD8 + T cells (5x10 5 ) were cultured with Na 2 51 CrO 4 (100 µCi/10 6 cells, NEN TM Life Science Products, Boston, MA)-labeled allogeneic fibroblasts derived from two different donors (10 4 ) for 4 h. The supernatants were harvested, the radioactivity (cpm) was measured, and the percentage of specific lysis was calculated. The removal of the immunomagnetic beads from the selected cells were performed by competitive detachment with mouse serum for 4 h, and they rested in medium for 16 h according to the manufacturer's instruction manual. After incubation, the residual immunomagnetic beads were removed by the magnetic particle concentrator (MPC-S, Dynal). A model of xenogeneic graft-versus-host disease (XGVHD) in SCID mice engrafted with human peripheral blood lymphocytes (hu-PBL-SCID mice) and murine allogeneic acute GVHD For xenogeneic transplantation, SCID mice (five animals in each group) were pretreated 1 day prior to the transplantation with a single dose (lyophilized Ab was resuspended in 1 ml of PBS, and 20 µl/mouse was given by intraperitoneal injection) of anti-asialo GM1 antiserum (the protein concentration was 10 mg/ml, WAKO, Osaka, Japan).
Analysis of Tr-cell function
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Immediately prior to the transplantation, SCID mice were exposed to a sublethal total body irradiation (5 Gy/mouse 
Results
Human modified DCs act as regulatory DCs to induce T-cell anergy
Modified iDCs expressed both the DC-marker (CD1a and CD11c) and the Langerhans cell-marker (E-cad), but not the monocyte/macrophage-marker (CD14) ( Figure 1A ). On the other hand, they showed moderately high expression levels of MHC molecules (HLA-A/B/C and HLA-DR) whereas they exhibited extremely low levels of costimulatory molecules (CD40, CD80 and CD86) as compared with normal iDCs ( Figures 1B, 1C and 1D ). Upon stimulation with TNF-, CD83 was detected whereas the DC-and the Langerhans cell-marker were downregulated ( Figure 1A ). In addition, the expression levels of MHC and costimulatory molecules were changed to various degrees following this stimulation ( Figures 1B, 1C and 1D ). We also observed that modified DCs were less effective for the activation of allogeneic CD4 + T cells than normal DCs and IL-10-treated iDCs (Figure 2A and 2B).
We examined the ability of allogeneic modified DCs to induce T-cell anergy. The primed naive CD4 + T cells with allogeneic normal DCs showed vigorous response to same donor-derived normal mDCs ( Figure 2A ). In contrast, the primed naive CD4 + T cells with allogeneic modified DCs were hyporesponsive to further stimulation with same donor-derived normal mDCs, and the addition of IL-2 to a second culture partly enhanced this response ( Figure 2A ). Similar results were observed when total CD4 + T cells were used as the responder cells, and the degree of modified DC-induced T-cell hyporesponsiveness was higher than that of IL-10-treated iDCs ( Figure 2B ).
Furthermore, allogeneic modified DCs induced anergic CD4 + T cells in a dose-dependent manner ( Figure 2C ), and they retained the hyporesponsiveness at least for 2 weeks ( Figure 2D ). In addition, the primed CD4 + T cells with allogeneic modified
DCs exhibited weaker response to the unrelated donor-derived allogeneic normal mDCs in a second culture than that primed with allogeneic normal DCs ( Figure 2A ).
We also examined the effect of modified DCs on allogeneic normal mDC-mediated activation of allogeneic CD4 + T cells ( Figure 2E ). Figure 3A ). We also 
Impairment of xenogeneic response of human T cells by murine regulatory DCs
There is an increasing interest in the xenogeneic organ transplantation in a clinical setting, and the suppression of human xenoreactive T cells is thought to be crucial for the xenogeneic organ transplantation. To test whether regulatory DCs can regulate xenoreactive T cells, we generated modified DCs from murine BM cells (H-2 
Discussion
Although DCs reportedly act as natural adjuvants to induce protective immunity against cancer and infectious diseases in humans, the strategy of the DC-mediated negative regulation of the T-cell response has not been established. To best our knowledge, this is the first paper to report that a group of human and murine DCs retain the potent immunoregulatory property in vitro and in vivo even under inflammatory conditions, and they show a protective effect on immunopathogenic disease.
We showed that the inflammatory stimulation failed to elicit a fully immunostimulatory maturational change in human regulatory iDCs whereas the maturation-associated change in several cell surface molecules was observed. Therefore, the maturational process may be selectively impaired in human regulatory DCs. These phenomena imply that the condition responsible for the induction of T-cell anergy by tolerant DCs is that the degree of T-cell activation in the priming is much lower than that on restimulation. Collectively, the characteristic expression profile of MHC and costimulatory molecules in regulatory DCs is associated with their potent anergye-inducing ability, in which they may deliver potent signal 1 plus poor signal 2 to alloreactive CD4 + T cells.
For 22 Further study will be needed to clarify the mechanism responsible for their inhibitory effect.
We showed that hu-PBL-SCID mice succumbed to XGVHD, and the transplanted human T cells obtained from hu-PBL-SCID mice responded to murine normal DCs. 
